

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Group Art Unit: Not-Yet-Assigned

Robert F. Rioux, et al

Examiner: Not-Yet-Assigned

Serial No.: 10/772,040

Filed: February 4, 2004

For: ABLATION PROBE FOR

**DELIVERING FLUID THROUGH POROUS** 

**STRUCTURE** 

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR § 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. Copies of US Patents and US Patent Publications are not enclosed, pursuant to the US Patent & Trademark Office waiver of this requirement under 37 CFR § 1.98 (a)(2)(i) for patent applications filed after June 30, 2003. Copies of other cited references are enclosed.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

## CERTIFICATE OF MAILING (37 C.F.R. §1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposit with the Unites States Postal Services on the date shown below with sufficient postage as "First Class Mail" to addressee in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313-1450

February 2+, 2004

Date of deposit PA:52129144.1/2024728-7034802001 Name of Person transmitting Pape

Signature of Person depositing Pape

2/27/04 11:05 AM

### Information Disclosure Statement Filing Provision:

filed ur 1.491; e	three monder § 1. or (3) be	S is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) on the filing date of the application, which is not a continued prosecution application 53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR § after the mailing of a first Office action on the merits; or (4) before the mailing of a first office filing a request for continued examination under § 1.114. Thus, no fee is required.			
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit account referenced below.			
		However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.			
on the 1 § 1.311					
		The fee due under 37 CFR § 1.17(p) is submitted herewith.			
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.			
-	or a No	os is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR office of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A r 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted			
		STATEMENT UNDER 37 CFR § 1.97(e):			
	Each ite	em contained in this IDS was first cited in any communication from a foreign patent office			
in a cou	ınterpar	t foreign application not more than three months prior to the filing of this IDS.			
	No iten	n contained in this IDS was cited in a communication from a foreign patent office in a			
counter	part for	eign application, and, to the knowledge of the person signing this statement after making			
reasonable inquiry, no item of information contained in this IDS was known to any individual designated					
in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.					

	PAYMENT AND/OR AUTHORIZATION	ON TO CHARGE FEES:						
	A check in the amount of is enclosed for the above fee(s).							
	Please charge to Deposit Account No. 50-2518 for the above fee(s).							
	Although applicant believes no fee is required, the Commissioner is authorized to charge any fees							
	required by the filing of these papers, and to credit any overpayment to Bingham McCutch							
	Deposit Account No. 50-2518.							
		Respectfully submitted, BIGHAM McCUTCHEN LLP						
Dated:	2/27/04 By:	David T. Burse Reg. No. 37,104						
-	HAM McCUTCHEN LLP							
Three 1	Embarcadero, Suite 1800	•						

23639

(650) 849-4400

PATENT TRADEMARK OFFICE

San Francisco, CA 94111-4067

Please type a plus sign (+) inside this box

MAR 0 1 2004

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

K O	Complete if Known		
Application Number	10/772,040		
Filing Date	February 4, 2004		
First Named Inventor	Robert F. Rioux, et al		
Group Art Unit	Not-Yet-Assigned		
Examiner Name	Not-Yet-Assigned		
Attorney Docket Number	28-7034802001 (03-253)		

OTHER DOCUMENTS NON PATENT LITERATURE							
Examiner Cite Initials * No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volu number(s), publisher, city and/or country where published.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	1.	AHMED, Muneeb, MD, et al "Improved Coagulation with Saline Solution Pretreatment during Radiofrequency Tumor Ablation in a Canine Model" J Vasc Interv Radiol 2002; 13: 717-724					
	2.	BOEHM, Thomas, MD, et al "Radio-frequency Tumor Ablation: Internally Cooled Electrode versus Saline- enhanced Technique in an Aggressive Rabbit Tumor Model" Radiology 2002; 222: 805-813					

Examiner Signature	 Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark hee if English language Translation is attached.